Pharmacogenomic Testing: A Path to Safer Medication

Pharmacogenomic (PGx) testing holds immense potential to improve medication safety and efficacy by tailoring treatments to an individual’s genetic profile. Despite its clear benefits, adoption in Australia remains limited due to cost and awareness challenges. The Royal College of Pathologists of Australasia (RCPA) is advocating for Medicare subsidies for critical tests, including those linked to chemotherapy metabolism (DPYD) and severe drug reactions (HLA).

Dr. Lan Nguyen underscores the importance of PGx testing in minimizing adverse reactions and optimizing prescriptions, particularly for medications with significant variability in patient response. The RCPA’s guidance provides robust recommendations for testing across a wide range of medications, including growing applications in oncology and psychiatry. Notably, general practitioners account for approximately 55% of test requests, reflecting a rising awareness of the role of PGx testing in everyday clinical care.

Pharmacogenomics is especially important for chronic conditions including but not limited to cardiovascular disease and mental health, where treatment safety and effectiveness are critical. For mental health applications, we are proud of our member GeneS and their leadership in providing pharmacogenomic solutions that help optimise medication choices, ensuring better outcomes for patients managing mental health conditions.

Expanding access to PGx testing represents a significant step toward advancing personalised medicine and enhancing patient safety across Australia—whether for over-the-counter medications or more specialised treatments.

For more information, read the full article on Medical Republic’s website.